TP53 mutation in colorectal cancer

Human Mutation

Volumn 21, Issue 3, 2003, Pages 271-276

  Iacopetta, Barry ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cancer; Chemotherapy; Colon; Colorectal; CRC; p53; Prognosis; TP53; Tumor

Indexed keywords

FLUOROURACIL; PROTEIN P53;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; DIAGNOSTIC VALUE; DRUG SENSITIVITY; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

COLORECTAL NEOPLASMS; GENE THERAPY; HUMANS; MUTATION; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 0037220169     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.10175     Document Type: Review

References (53)

1. Adrover E, Maestro ML, Sanz-Casla MT, del Barco V, Cerdan J, Fernandez C, Balibrea JL. 1999. Expression of high p53 levels in colorectal cancer: a favourable prognostic factor. Br J Cancer 81:122-126.
2. Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA Jr, Stemmerman G, Wells JD, Macdonald JS, Meyskens FL Jr. 1998. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 58:1149-1158.
3. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lovig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N. 1998. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 90:675-684.
4. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR. 1994. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5-12.
5. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, vanTuinen P, Ledbetter DH, Barker DF, Nakamura Y. 1989. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217-221.
6. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. 1990. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-915.
7. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GE, Taylor GR, Dixon MF, Quirke P. 1993. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 104:57-64.
8. Berggren P, Steineck G, Hemminki K. 2000. A rapid fluorescence based multiplex polymerase chain reaction - single-strand conformation polymorphism method for p53 mutation detection. Electrophoresis 21:2335-2342.
9. Beroud C, Soussi T 2003. The UMD-p53 database: new mutations and analysis tools. Hum Mutat 21:176-181.
10. Børresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E. 1998. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 4:203-210.
11. Bosari S, Viale G, Bossi P, Maggioni M, Coggi G, Murray JJ, Lee AK. 1994. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 86:681-687.
12. Bosari S, Marchetti A, Buttitta F, Graziani D, Borsani G, Loda M, Bevilacqua G, Coggi G. 1995. Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis. A comparative study of radioactive and nonradioactive silver-stained SSCP analysis. Diagn Mol Pathol 4:249-255.
13. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. 1999. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263-269.
14. Cripps KJ, Purdie CA, Carder PJ, White S, Komine K, Bird CC, Wyllie AH. 1994. A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma. Oncogene 9:2739-2743.
15. Delattre O, Olschwang S, Law DJ, Melot T, Remvikos Y, Salmon RJ, Sastre X, Validire P, Feinberg AP, Thomas G. 1989. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 2(8659):353-356.
16. Diez M, Medrano M, Muguerza JM, Ramos P, Hernandez P, Villeta R, Martin A, Noguerales F, Ruiz A, Granell J. 2000. Influence of tumor localization on the prognostic value of p53 protein in colorectal adenocarcinomas. Anticancer Res 20:3907-3912.
17. Dix B, Robbins P, Carrello S, House A, Iacopetta B. 1994. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer 70:585-590.
18. Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, Iacopetta B. 2001. p53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 7:1343-1349.
19. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L, Benhattar J. 1995. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92: 3963-3967.
20. Goh HS, Yao J, Smith DR. 1995. p53 point mutation and survival in colorectal cancer patients. Cancer Res 55: 5217-5221.
21. Hamelin R, Jego N, Laurent-Puig P, Vidaud M, Thomas G. 1993. Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene 8:2213-2220.
22. Iacopetta B, Elsaleh H, Grieu F, Joseph D, Sterrett G, Robbins P. 2000. Routine analysis of p53 mutation in clinical breast tumor specimens using fluorescence-based polymerase chain reaction and single strand conformation polymorphism. Diagn Mol Pathol 9:20-25.
23. Iniesta P, Vega FJ, Caldes T, Massa M, de Juan C, Cerdan FJ, Sanchez A, Lopez JA, Torres AJ, Balibrea JL, Benito M. 1998. p53 exon 7 mutations as a predictor of poor prognosis in patients with colorectal cancer. Cancer Lett 130:153-160.
24. Jernvall P, Makinen M, Karttunen T, Makela J, Vihko P. 1997. Conserved region mutations of the p53 gene are concentrated in distal colorectal cancers. Int J Cancer 74:97-101.
25. Kressner U, Lindmark G, Gerdin B, Pahlman L, Glimelius B. 1996. Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res 16:951-957.
26. Kressner U, Inganas M, Byding S, Blikstad I, Pahlman L, Glimelius B, Lindmark G. 1999. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 17: 593-599.
27. Liang JT, Huang KC, Cheng YM, Hsu HC, Cheng AL, Hsu CH, Yeh KH, Wang SM, Chang KJ. 2002. p53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer 97:451-457.
28. Makino R, Kaneko K, Kurahashi T, Matsumura T, Mitamura K. 2000. Detection of mutation of the p53 gene with high sensitivity by fluorescence-based PCR-SSCP analysis using low-pH buffer and an automated DNA sequencer in a large number of DNA samples. Mutat Res 452:83-90.
29. Manne U, Myers RB, Moron C, Poczatek RB, Dillard S, Weiss H, Brown D, Srivastava S, Grizzle WE. 1997. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 74:346-358.
30. Manne U, Weiss HL, Myers RB, Danner OK, Moron C, Srivastava S, Grizzle WE. 1998. Nuclear accumulation of p53 in colorectal adenocarcinoma: prognostic importance differs with race and location of the tumor. Cancer 83:2456-2467.
31. Moyret C, Theillet C, Laurent-Puig P, Moles JP, Thomas G, Hamelin R. 1994. Relative efficiency of denaturing gradient gel electrophoresis and single strand conformation polymorphism in the detection of mutations in exons 5 to 8 of the p53 gene. Oncogene 9:1739-1743.
32. Mulder JW, Baas IO, Polak MM, Goodman SN, Offerhaus GJ. 1995. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 71:1257-1262.
33. Poller DN, Baxter KJ, Shepherd NA. 1997. p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer? Br J Cancer 75:87-93.
34. Purdie CA, O'Grady J, Piris J, Wyllie AH, Bird CC. 1991. p53 expression in colorectal tumors. Am J Pathol 138: 807-813.
35. Remvikos Y, Laurent-Puig P, Salmon RJ, Frelat G, Dutrillaux B, Thomas G. 1990. Simultaneous monitoring of p53 protein and DNA content of colorectal adenocarcinomas by flow cytometry. Int J Cancer 45:450-456.
36. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP. 1990. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87:7555-7559.
37. Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF, Slattery ML. 2002. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 99:597-602.
38. Smith DR, Ji CY, Goh HS. 1996. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 74:216-223.
39. Soong R, Iacopetta BJ. 1997. A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors. Mod Pathol 10:252-258.
40. Soong R, Grieu F, Robbins P, Dix B, Chen D, Parsons R, House A, Iacopetta B. 1997. p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 3:1405-1411.
41. Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS, Joseph D, Iacopetta B. 2000. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 36:2053-2060.
42. Soussi T, Dehouche K, Beroud C. 2000. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat 15:105-113.
43. Soussi T, Beroud C. 2003. Significance of p53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum Mutat 21:192-200.
44. Starzynska T, Bromley M, Ghosh A, Stern PL. 1992. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 66:558-562.
45. Starzynska T, Bromley M, Marlicz K, Roberts SA, Ucinski M, Stern PL. 1997. Accumulation of p53 in relation to long-term prognosis in colorectal carcinoma. Eur J Gastroenterol Hepatol 9:183-186.
46. Sun XF, Carstensen JM, Zhang H, Stal O, Wingren S, Hatschek T, Nordenskjold B. 1992. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 340(8832):1369-1373.
47. Sun XF, Carstensen JM, Zhang H, Arbman G, Nordenskjold B. 1996. Prognostic significance of p53 nuclear and cytoplasmic overexpression in right and left colorectal adenocarcinomas. Eur J Cancer 32A:1963-1967.
48. Tollenaar RA, van Krieken JH, van Slooten HJ, Bruinvels DJ, Nelemans KM, van den Broek LJ, Hermans J, van Dierendonck JH. 1998. Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: no evidence for prognostic significance. Br J Cancer 77:1842-1847.
49. Tortola S, Marcuello E, Gonzalez I, Reyes G, Arribas R, Aiza G, Sancho FJ, Peinado MA, Capella G. 1999. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 17:1375-1381.
50. Veloso M, Wrba F, Kaserer K, Heinze G, Magalhaes A, Herbst F, Teleky B. 2000. p53 gene status and expression of p53, mdm2, and p21Waf1/Cip1 proteins in colorectal cancer. Virchows Arch 437:241-247.
51. Yamaguchi A, Kurosaka Y, Fushida S, Kanno M, Yonemura Y, Miwa K, Miyazaki I. 1992. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 70:2778-2784.
52. Yamaguchi A, Nakagawara G, Kurosaka Y, Nishimura G, Yonemura Y, Miyazaki I. 1993. p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 68:399-402.
53. Zeng ZS, Sarkis AS, Zhang ZF, Klimstra DS, Charytonowicz E, Guillem JG, Cordon-Cardo C, Cohen AM. 1994. p53 nuclear overexpression: an independent predictor of survival in lymph node - positive colorectal cancer patients. J Clin Oncol 12:2043-2050.